Sincere Capital
Sincere Capital is a venture capital firm based in Shanghai, China, founded in 2015 by experienced investment specialists. The firm focuses on early and late-stage investments across various sectors, including hard and core technology, intelligent manufacturing, entertainment, healthcare, clean technology, and financial technology. It has a particular interest in technology innovations such as the Internet of Things (IoT), where it seeks opportunities in semiconductors, new materials, sensors, and high-end equipment. In the biotechnology sector, Sincere Capital targets innovative medicine, medical equipment, and precision medicine. The firm aims to exit its investments primarily through mergers and acquisitions or initial public offerings. Additionally, it is actively involved in state-owned enterprise reforms, contributing to the modernization and efficiency of these entities.
Cullgen Inc. is a biopharmaceutical company based in San Diego, California, established in 2018. The company focuses on developing innovative new chemical entities (NCEs) aimed at treating diseases that currently lack effective therapeutic options. Utilizing its proprietary uSMITE™ platform, Cullgen employs targeted protein degradation technology to selectively degrade disease-causing proteins. This approach is particularly significant for addressing cancer, inflammatory, and autoimmune diseases, including targets that have been deemed undruggable. By providing novel therapeutic strategies, Cullgen aims to enhance drug discovery and offer new avenues for treating debilitating conditions.
Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases.
Seetrum is an electronics manufacturing firm that provides advanced spectroscopy chips, AI algorithms, and smart perception solutions.
Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical company founded in 2017 and based in Shanghai, China. It specializes in the research, development, manufacturing, and sales of macromolecular drugs, including therapeutic monoclonal antibodies, vaccines, and long-acting recombinant proteins. The company's product pipeline encompasses over thirty drug varieties targeting conditions such as tumors, autoimmunity, infections, and ophthalmic diseases. Currently, six of these products are in clinical development, with three advancing to Phase III clinical trials. Mabwell has established a strong presence in the biopharmaceutical sector by integrating multiple R&D and production enterprises within the Zhangjiang Hi-Tech Park.
HiScene Information Technology Co., Ltd specializes in the research and development of augmented reality technologies and products. Founded in 2012 and based in Shanghai, China, the company offers a range of solutions, including the HiAR technology infrastructure platform and HiAR Glasses, which are equipped with multiple cameras and sensors to track user movements and create three-dimensional spatial models. HiScene integrates advanced artificial intelligence technologies, such as computer vision and deep learning, into its hardware and software offerings, aiming to enhance human-computer interaction and deliver industry-specific solutions. Through its innovations, the company seeks to improve operational efficiency and safety in engineering and industrial applications.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.